Aclaris Therapeutics Hits New 52-Week High of $5.34, Up 399%

Aclaris Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.34 on June 30, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 399.06%, significantly outpacing the S&P 500's performance of 20.86% during the same period. The company's market capitalization stands at USD 424 million, reflecting its position within the microcap category. Despite its recent stock performance, Aclaris Therapeutics is currently operating at a loss, as indicated by its negative price-to-earnings ratio and a return on equity of -60.56%. The stock's price-to-book ratio is 4.12, suggesting that investors are valuing the company at a premium relative to its book value. With a 52-week low of USD 1.38, the recent high underscores the volatility and potential for growth within the stock. Aclaris Therapeutics continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology industry.